prinomastat
Prinomastat is a matrix metalloproteinase (MMP) inhibitor with specific selectivity for MMPs 2, 3, 9, 13, and 14. Investigations have been carried out to determine whether the inhibition of these MMPs is able to block tumour metastasis by preventing MMP degradation of the extracellular matrix proteins and angiogenesis. Prinomastat underwent a Phase III trial to investigate its effectiveness against non-small cell lung cancer (NSCLC), in combination with gemcitabine chemotherapy. However, it was discovered that Prinomastat did not improve the outcome of chemotherapy in advanced non-small-cell lung cancer. — Wikipedia
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Earliest trial started Mar 1, 1998 (NCT00003343)
Timeline
Indications
Mechanism of action
- Matrix metalloproteinase 9INHIBITOR
MMP9 inhibitor
- Matrix metalloproteinase 14INHIBITOR
MMP14 inhibitor
- Matrix metalloproteinase 13INHIBITOR
MMP13 inhibitor
- Matrix metalloproteinase 15INHIBITOR
MMP15 inhibitor
Chemistry & pharmacology
SMILES
CC1(C)SCCN(S(=O)(=O)c2ccc(Oc3ccncc3)cc2)[C@H]1C(=O)NO- Mol. weight
- 423.52 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPrinomastat ↗
- ChEMBLCHEMBL75094 ↗
Also known as
- ag3340
- ag 3340
- ag-3340
- ag-3340
- ag-3340
- prinomastat
- prinomastat
- prinomastat
- prinomastat
- prinomastat
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00004200 | Phase 2 | Oct 1, 1999 | Agouron, Pfizer |
| NCT00004199 | Phase 3 | Mar 1, 1999 | Agouron, Pfizer |
| NCT00003343 | Phase 3 | Mar 1, 1998 | Agouron, Pfizer |